{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T20:12:05Z","timestamp":1784923925404,"version":"3.55.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction and Purpose<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD) care is moving from a symptom-driven step-up model of care toward earlier effective intervention, complication-specific management, and more personalized treatment selection. This review synthesizes selected ECCO 2026 studies and offers an expert appraisal of their clinical relevance, methodological strengths, and remaining uncertainties. Particular emphasis is placed on studies most likely to influence current practice and further research, including late-breaking trials, complication-directed therapy, pediatric evidence, and technology-assisted assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary of Findings<\/jats:title>\n                    <jats:p>Study findings spanned both ulcerative colitis (UC) and Crohn\u2019s disease (CD). New therapeutic studies presented included the phase 3 study of vedolizumab in pediatric UC, phase 2 efficacy data for picankibart in UC, and regenerative fistula data of AVB-114 in perianal CD. Real-world data presented included comparative data on different Janus kinase inhibitors in UC. Updates on interleukin-23 included durable extension data in UC, as well as efficacy data in advanced therapy\u2011exposed patients (mirikizumab in UC and risankizumab in CD). Innovative technologies included transperineal ultrasound for early identification of steroid non-response in acute severe UC, and multimodal artificial intelligence for Mayo endoscopic scoring. Beyond drug therapy, the 10-year LIR! C follow-up provided further data on surgical intervention as an early strategy in selected uncomplicated ileal CD, while the Preventing IBD ONset in Individuals at Risk study investigated potential benefits of a whole-food diet in high-risk first-degree relatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Next Steps<\/jats:title>\n                    <jats:p>ECCO 2026 emphasized durable, precision-oriented, multidisciplinary, and technology-enabled IBD care across the full continuum, from prevention to long-term modification. Apart from phase 3 and extension trials, other results remain preliminary and need broader comparative and practice-embedded studies before widespread adoption.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/crocol\/otag075","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T11:33:25Z","timestamp":1783251205000},"source":"Crossref","is-referenced-by-count":0,"title":["Highlights of the 2026 European Crohn\u2019s and Colitis Conference: redefining the IBD care continuum"],"prefix":"10.1093","volume":"8","author":[{"given":"Ahmed","family":"Al-Hindawi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, CHI Health Creighton University Medical Center\u2014Bergan Mercy , Omaha, NE,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Siegel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, CHI Health Creighton University Medical Center\u2014Bergan Mercy , Omaha, NE,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive Jude","family":"Miranda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHI Health Creighton University Medical Center\u2014Bergan Mercy , Omaha, NE,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Maddineni","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, CHI Health Creighton University Medical Center\u2014Bergan Mercy , Omaha, NE,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-3956","authenticated-orcid":false,"given":"Mohammad","family":"Shehab","sequence":"additional","affiliation":[{"name":"Program of Medicine, College of Medicine and Health Sciences, Abdullah Al Salem University , Kuwait City,","place":["Kuwait"]},{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, McGill University Health Center , Montreal,","place":["Canada"]},{"name":"Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital , Jabriya,","place":["Kuwait"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"2026072415341383200_otag075-B1","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B3","doi-asserted-by":"crossref","first-page":"ii31","DOI":"10.1093\/ecco-jcc\/jjae087","article-title":"Considerations in paediatric and adolescent inflammatory bowel disease","volume":"18","author":"Vuijk","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"2026072415341383200_otag075-B5","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1097\/MIB.0000000000000918","article-title":"Vedolizumab therapy in severe pediatric inflammatory bowel disease","volume":"22","author":"Conrad","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026072415341383200_otag075-B6","doi-asserted-by":"crossref","first-page":"otab039","DOI":"10.1093\/crocol\/otab039","article-title":"Vedolizumab experience in children and adolescents with inflammatory bowel disease: a multicenter observational study","volume":"3","author":"Hajjat","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"2026072415341383200_otag075-B7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/jgh.16246","article-title":"Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan","volume":"38","author":"Yokoyama","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"2026072415341383200_otag075-B8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(22)00307-7","article-title":"Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study","volume":"8","author":"Atia","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026072415341383200_otag075-B9","doi-asserted-by":"crossref","first-page":"jjaf231.074","DOI":"10.1093\/ecco-jcc\/jjaf231.074","article-title":"DOP037 efficacy and safety of intravenous vedolizumab in paediatric patients with moderate-to-severe ulcerative colitis: results from the KEPLER phase 3 trial","volume":"20","author":"Turner","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B10","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1007\/s12325-025-03419-w","article-title":"Efficacy and safety of switching to picankibart from non-interleukin-23 subunit p19 inhibitors in patients with plaque psoriasis: a multicenter, open-label, phase 2 trial","volume":"43","author":"Yang","year":"2026","journal-title":"Adv Ther"},{"key":"2026072415341383200_otag075-B11","doi-asserted-by":"crossref","first-page":"jjaf231.095","DOI":"10.1093\/ecco-jcc\/jjaf231.095","article-title":"DOP058 efficacy and safety of picankibart in patients with moderately to severely active ulcerative colitis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"20","author":"Chen","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B12","volume-title":"Efficacy and Safety of Picankibart in Patients with Moderately to Severely Active Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Trial","author":"Chen","year":"2026"},{"key":"2026072415341383200_otag075-B13","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026072415341383200_otag075-B14","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn\u2019s disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"2026072415341383200_otag075-B15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"2026072415341383200_otag075-B16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/DCR.0000000000002579","article-title":"Durable response in patients with refractory fistulizing perianal Crohn\u2019s disease using autologous mesenchymal stem cells on a dissolvable matrix: results from the phase I stem cell on matrix plug trial","volume":"66","author":"Dozois","year":"2023","journal-title":"Dis Colon Rectum"},{"key":"2026072415341383200_otag075-B17","doi-asserted-by":"crossref","first-page":"jaf231.045","DOI":"10.1093\/ecco-jcc\/jjaf231.045","article-title":"DOP008 expanded primary analysis of the randomized, wait-list controlled STOMP2 trial evaluating AVB-114 in persistent Crohn\u2019s perianal fistulas","volume":"20","author":"Schwartz","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B18","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"2026072415341383200_otag075-B19","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"2026072415341383200_otag075-B20","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"2026072415341383200_otag075-B21","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/apt.18406","article-title":"Comparative efficacy and safety of three janus kinase inhibitors in ulcerative colitis: a real-world multicentre study in Japan","volume":"61","author":"Akiyama","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072415341383200_otag075-B22","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf231.119","article-title":"Dop082 real-world effectiveness and safety of three JAK inhibitors for ulcerative colitis: an IPTW analysis from IN-IBD","volume":"20","author":"Mocci","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B23","doi-asserted-by":"crossref","first-page":"1699928","DOI":"10.3389\/fphar.2025.1699928","article-title":"Safety and efficacy of different JAK inhibitors in the treatment of inflammatory bowel disease: a network meta-analysis","volume":"16","author":"Wu","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026072415341383200_otag075-B24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of janus kinase inhibitors in inflammatory bowel diseases","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"key":"2026072415341383200_otag075-B25","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis: QUASAR phase 2b induction study","volume":"165","author":"Peyrin-Biroulet","year":"2023","journal-title":"Gastroenterology"},{"key":"2026072415341383200_otag075-B26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"2026072415341383200_otag075-B27","doi-asserted-by":"crossref","first-page":"jjaf231.141","DOI":"10.1093\/ecco-jcc\/jjaf231.141","article-title":"DOP104 efficacy and safety of guselkumab for ulcerative colitis through week 140 of the QUASAR long-term extension study","volume":"20","author":"Peyrin-Biroulet","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B28","volume-title":"Efficacy and Safety of Guselkumab for Ulcerative Colitis through Week 140 of the QUASAR Long-Term Extension Study","author":"Peyrin-Biroulet","year":"2026"},{"key":"2026072415341383200_otag075-B29","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"2026072415341383200_otag075-B30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"2026072415341383200_otag075-B31","doi-asserted-by":"crossref","first-page":"jjaf025","DOI":"10.1093\/ecco-jcc\/jjaf025","article-title":"Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis","volume":"19","author":"Reinisch","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B32","doi-asserted-by":"crossref","first-page":"jjaf005","DOI":"10.1093\/ecco-jcc\/jjaf005","article-title":"Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies","volume":"19","author":"Panaccione","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B33","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf231.092","article-title":"DOP055 efficacy and safety up to 3 years of risankizumab maintenance treatment in patients with moderately to severely active ulcerative colitis: Interim results from phase 3 COMMAND Open-Label Extension Study","volume":"20","author":"Atreya","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B34","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1007\/s10620-025-08950-y","article-title":"Mirikizumab in the treatment of ulcerative colitis: initial real-world data in a population from a large tertiary center","volume":"70","author":"St-Pierre","year":"2025","journal-title":"Dig Dis Sci"},{"key":"2026072415341383200_otag075-B35","doi-asserted-by":"crossref","first-page":"jjaf231.067","DOI":"10.1093\/ecco-jcc\/jjaf231.067","article-title":"DOP030 real-world effectiveness and safety of mirikizumab in refractory, biologic-experienced ulcerative colitis patients","volume":"20","author":"Melotti","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B36","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf231.067","volume-title":"Real-World Effectiveness and Safety of Mirikizumab in Refractory, Biologic-Experienced Ulcerative Colitis Patients","author":"Melotti","year":"2026"},{"key":"2026072415341383200_otag075-B37","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet"},{"key":"2026072415341383200_otag075-B38","doi-asserted-by":"crossref","first-page":"jjaf231.068","DOI":"10.1093\/ecco-jcc\/jjaf231.068","article-title":"DOP031 analysis of Long-Term safety and efficacy of risankizumab in patients with moderate-to-severe Crohn\u2019s disease: 3-year results from the SEQUENCE study","volume":"20","author":"Peyrin-Biroulet","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"key":"2026072415341383200_otag075-B40","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/apt.15767","article-title":"Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis","volume":"51","author":"Sagami","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026072415341383200_otag075-B41","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review","volume":"17","author":"Gisbert","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B42","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026072415341383200_otag075-B43","doi-asserted-by":"crossref","first-page":"jjaf231.048","DOI":"10.1093\/ecco-jcc\/jjaf231.048","article-title":"DOP011 TRANSPIRE: TRANSperineal ultrasound parameters for identifying steroid non-response in patients with acute seveRE ulcerative colitis: an interim analysis","volume":"20","author":"Subhaharan","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B44","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf231.048","volume-title":"TRANSPIRE: TRANSperineal Ultrasound Parameters for Identifying Steroid Non-Response in Patients with Acute seveRE Ulcerative Colitis: An Interim Analysis","author":"Subhaharan","year":"2026"},{"key":"2026072415341383200_otag075-B45","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ibd\/izae051","article-title":"Inter- and intraobserver variability on endoscopic scoring systems in Crohn\u2019s disease and ulcerative colitis: a systematic review and meta-analysis","volume":"30","author":"Hashash","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026072415341383200_otag075-B46","doi-asserted-by":"crossref","first-page":"jjaf231.129","DOI":"10.1093\/ecco-jcc\/jjaf231.129","article-title":"DOP092 comparative evaluation of multimodal large language models for computer-assisted endoscopic assessment in ulcerative colitis","volume":"20","author":"Zhao","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2026072415341383200_otag075-B48","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/ecco-jcc\/jjae089","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: surgical treatment","volume":"18","author":"Adamina","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B49","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2468-1253(17)30248-0","article-title":"Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn\u2019s disease: a randomised controlled, open-label, multicentre trial","volume":"2","author":"Ponsioen","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026072415341383200_otag075-B50","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S2468-1253(20)30117-5","article-title":"Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn\u2019s disease: retrospective long-term follow-up of the LIR! C trial","volume":"5","author":"Stevens","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026072415341383200_otag075-B51","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S2468-1253(25)00374-7","article-title":"Ileocaecal resection versus infliximab for ileal Crohn\u2019s disease: retrospective 10-year follow-up of the LIR! C trial","volume":"11","author":"Oldenburg","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026072415341383200_otag075-B52","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"2026072415341383200_otag075-B53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.gastro.2025.09.042","article-title":"prediction and prevention of inflammatory bowel disease: a call to action","volume":"170","author":"Lee","year":"2026","journal-title":"Gastroenterology"},{"key":"2026072415341383200_otag075-B54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2024.08.031","article-title":"Healthy First-Degree relatives from multiplex families vs simplex families have higher subclinical intestinal inflammation, a distinct fecal microbial signature, and harbor a higher risk of developing Crohn\u2019s disease","volume":"168","author":"Olivera","year":"2025","journal-title":"Gastroenterology"},{"key":"2026072415341383200_otag075-B55","article-title":"Preclinical stages of Crohn\u2019s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials","author":"Turner","year":"2026","journal-title":"Gut"},{"key":"2026072415341383200_otag075-B56","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2025.06.011","article-title":"Whole food diet induces remission in children and young adults with mild to moderate Crohn\u2019s disease and is more tolerable than exclusive enteral nutrition: a randomized controlled trial","volume":"169","author":"Aharoni-Frutkoff","year":"2025","journal-title":"Gastroenterology"},{"key":"2026072415341383200_otag075-B57","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf231.017","article-title":"OP17 the Tasty&Healthy whole food diet improves calprotectin in high risk first-degree relatives of patients with Crohn\u2019s disease (FDRs): the PIONIR randomized controlled prevention cross-over trial","volume":"20","author":"Turner","year":"2026","journal-title":"J Crohns Colitis"},{"key":"2026072415341383200_otag075-B58","volume-title":"The Tasty&Healthy Whole Food Diet Improves Calprotectin in High Risk First-Degree Relatives of Patients with Crohn\u2019s Disease (FDRs): The PIONIR Randomized Controlled Prevention Cross-over Trial","author":"Turner","year":"2026"}],"container-title":["Crohn\u2019s &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otag075\/68707399\/otag075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag075\/68707399\/otag075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/8\/3\/otag075\/68707399\/otag075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:34:26Z","timestamp":1784921666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otag075\/8726059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otag075","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"otag075"}}